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The TRPV4 (transient receptor potential vanilloid 4) ion channel, a member of the vanilloid subfamily of the TRP channels, is activated by membrane stretch, by non-noxious warm temperatures, and by a range of chemical activators. In the present study we examined the role of phosphorylation in modulating activation of TRPV4. We expressed TRPV4 in HEK293 cells and activated the channel by cell swelling in a hypotonic solution. TRPV4 channel activation and serine phosphorylation were enhanced by exposure to the PKC activator phorbol 12-myristate 13-acetate (PMA) or by application of bradykinin, which activates PKC via a G-protein coupled mechanism. The enhancement was inhibited by the PKC inhibitors staurosporine, BIM, and rottlerin, or by mutation of the serine/threonine residues S162, T175 and S189. The adenylate cyclase activator forskolin (FSK) also enhanced activation of TRPV4, and the enhancement was antagonized by the selective PKA inhibitor H89 or by mutation of serine residue S824. Sensitization of TRPV4 by both PKC and PKA depended on the scaffolding protein AKAP79, because channel activation and phosphorylation were enhanced by co-transfection of AKAP79 and were antagonized by removal of AKAP79 using siRNA.  We conclude that the S/T kinases PKC and PKA enhance activation of the TRPV4 ion channel by phosphorylation at specific sites, and that phosphorylation depends on assembly of PKC and PKA by AKAP79 into a signaling complex with TRPV4.

TRPV4 was cloned from kidney, hypothalamus and auditory epithelium and was given a number of names: Osm-9-like TRP channel 4 (OTRPC4) (1), VR-OAC (2), TRP12 (3) and vanilloid receptor-like channel 2 (VRL-2) (4). The gene for human TRPV4 is located on chromosome 12q23-q24.1 and has 15 exons, which code for a full-length protein with 871 amino acids. TRPV4 is a member of the TRPV subfamily of TRP channels, and like other members of this subfamily it is a polymodal receptor activated by a wide variety of stimuli. TRPV4 is strongly expressed in kidney and is activated by hypotonicity, which has led to the suggestion that TRPV4 is an osmosensor important in regulating body fluid levels (5-10). However, TRPV4 is also activated by innocuous heat with a threshold > 27C (11-13), by the phorbol ester 4-phorbol 12,13-didecanoate (4PDD) (14;15), by low pH (16), by endocannabinoids and arachidonic acid metabolites (17;18), by the active compound, bisandrographolide A, of Andrographis paniculata, a Chinese herbal plant (19) and by nitric oxide (20). TRPV4 is expressed in a broad range of tissues, including lung, spleen, kidney, testis, fat, brain, cochlea, skin, smooth muscle, liver, vascular endothelium (21-23), in the lamina terminalis of the mouse brain, in neurons of the arched vascular organ of the lamina terminalis (VOLT), in the median preoptic area, the optic chiasm, neurons of the subfornical organ, the ventral hippocampal commissure, anterior hypothalamic structures, ependymal cells of the choroid plexus in the lateral ventricles, and dorsal root ganglia (DRG) neurons (24-26). The broad spectrum of activators and the wide distribution of TRPV4 suggest that the functions of TRPV4 extend beyond osmosensation. 
TRPV4 has been proposed to play a role in the mechanical hyperalgesia that is generated by the concerted action of inflammatory mediators present in inflamed tissues (27). After tissue injury, inflammatory mediators such as bradykinin, PGE2, 5-HT and histamine directly sensitize primary afferent neurons, resulting in hyperalgesia (reviewed in 28). Important intracellular signaling molecules contributing to inflammatory hyperalgesia include protein kinase C (PKC) (29;30) and cyclic AMP-dependent protein kinase (PKA) (31). For example, the activation of the Gq-coupled B1 and B2 receptors by bradykinin leads to the release of a range of potential intracellular messengers, with a substantial body of evidence favouring the idea that the temperature threshold of TRPV1 is lowered by PKC-mediated phosphorylation (32-35). PKA, like PKC, is a critical intracellular signalling molecule mediating inflammatory hyperalgesia (36). In sensory neurons PGE2 activates both the EP1 receptor, which is Gq-coupled and therefore activates PKC, and the EP4 receptor, which is Gs-coupled and therefore activates PKA. Cyclic AMP analogues, the adenylate cyclase activator, forskolin (FSK), or phosphodiesterase inhibitors enhance the mechanical and thermal hyperalgesic effects of PGE2 (37-39). Thus PKC and PKA have a vital role to play in the process of inflammatory hyperalgesia. 
The speed and specificity of the action of kinases is in many cases enhanced by binding to scaffolding proteins, which pre-assemble the kinases into signalling complexes with their target substrates. The AKAP (A Kinase Anchoring Protein) family of scaffolding proteins was originally named for their ability to target PKA to appropriate substrates, but are now known to assemble a wide range of kinases and phosphatases into signalling complexes with appropriate targets (40). A number of ion channels are subject to modulation by AKAPs, including glutamate receptors, calcium channels and the M-type potassium channels (41-44). The heat-activated ion channel TRPV1, a member of the same subfamily as TRPV4, has recently been shown to be assembled into a signaling complex with PKA, PKC, and PP2B by AKAP79, and the sensitization of TRPV1 by PKC and PKA is critically reliant on binding to AKAP79 (45). 







Cell culture and transfection. HEK293 cells (ATCC) were maintained in DMEM supplemented with 10% FBS, 50U/ml penicillin, 50μg/ml streptomycin and 20mM L-glutamine. Cells were transiently transfected using PolyFect reagent (Qiagen) in accordance with the manufacturer’s instructions with some modification as follows. Briefly, 2μg DNA was diluted in a total volume of 100μl serum free medium and mixed with 10μl PolyFect transfection reagent, followed by 10 minutes room temperature incubation to allow DNA complex formation, 0.6ml of growth medium was added to the transfection complexes, DNA solution was transferred to the cells and was incubated for 24 hours. 
Plasmid and DNA construction. Potential TRPV4 PKC and PKA phosphorylation sites were sought by using GPS (http://973-proteinweb.ustc.edu.cn/gps/gps_web/predict.php (​http:​/​​/​973-proteinweb.ustc.edu.cn​/​gps​/​gps_web​/​predict.php​)) (46), PredPhospho (www.pred.ngri.re.kr/PredPhospho.htm (​http:​/​​/​www.pred.ngri.re.kr​/​PredPhospho.htm​)) (47), NetPhosK  (www.cbs.dtu.dk/services/NetPhosK (​http:​/​​/​www.cbs.dtu.dk​/​services​/​NetPhosK​)) (48), and ScanSite (www.scansite.mit.edu (​http:​/​​/​www.scansite.mit.edu​)) (49). Potential phosphorylation sites were targeted when they were identified with high probability by one or more of these packages. 
The siRNA against AKAP79 was constructed in a  plasmid co-expressing GFP to facilitate identification of successfully transfected cells, as previously described (45). We thank the following for kind gifts of plasmids: hTRPV4 tagged with V5, Dr David Cohen; AKAP79, Dr John Scott; hB2 receptor, Dr Tanya O’Neill. 
Point mutations were introduced into TRPV4 by using QuikChange (Stratagene) site directed mutagenesis in accordance with the manufacturer´s instructions. The S189A/T175A double mutant was constructed by combination of the S189A site mutant together with the T175A mutant. The S162A/S189A/T175A triple mutant was constructed by combination of the S162A site mutant together with the double mutant S189A/T175A. All constructs were verified by DNA sequencing (Department of Biochemistry, University of Cambridge). The cDNAs were subcloned into the pcDNA3 vector (Invitrogen) for amplification and transfection.
Imaging of intracellular calcium and data analysis. Calcium imaging was performed as described previously (Bonnington et al., 2003). Briefly, HEK293 cells were transiently transfected with 2μg TRPV4 cDNA (WT or mutant), or cotransfected with 0.67μg wtTRPV4 cDNA + 1.33μg AKAP79 or siRNA AKAP79 for 24 hours. Cells were plated onto 13mm polylysine-treated cover slips and grown for one day, loaded with 10μM fluo-4 AM (Molecular Probes) for 40 minutes, and were then mounted into a chamber which was continuously perfused with an isotonic solution (100 mM NaCl, 2 mM CaCl2, 4mM KCl, 1 mM MgCl2, 10 mM HEPES, 10 mM glucose, 100 mM Mannitol,  pH 7.4, osmolarity 320 ± 5 milliosm). [Ca2+]i was monitored with an inverted confocal microscope (BioRad). Cell swelling was induced by omitting mannitol from this solution (230 ± 5 milliosm). Fluo-4 AM was excited at 488 nm, and images of the fluorescence, F, were captured every 3 seconds. At the end of the experiment, the maximal fluorescence (Fmax) was obtained by application of the calcium ionophore ionomycin (10 µM). The Ca2+-dependent fluorescence changes were calibrated as described (50). Data are expressed as F/Fmax. Inhibitors were applied for 30 minutes before treatment with e.g. PMA, FSK or bradykinin. Significance was tested using one-way analysis of variance (ANOVA) with Bonferroni’s post hoc test (SPSS for Windows). Significance levels in figures are given as: ns, not significant, >5%; *, <5%; **, <1%; ***, <0.1%. All errors shown as bars in Figures or quoted in the text are ± SEM. All experiments were performed at room temperature (20–22°C).




TRPV4 sensitization by PKC activation. We used HEK293 cells transfected with plasmids containing cDNAs coding for TRPV4 to investigate the sensitization of TRPV4. Hypotonic solutions were used to activate TRPV4 (51-53). The calcium influx through the TRPV4 channel, whether activated by heat or by hypotonic solutions, is sensitized by inflammatory mediators in a similar manner (54;55). Transfected cells were loaded with the intracellular calcium indicator fluo-4 and imaged in a confocal microscope. The increase in calcium-dependent fluorescence (∆F) caused by applying a hypotonic solution was used as an index of the activation of TRPV4 (Figure 1A). There was no increase in Ca-dependent fluorescence either in untransfected cells or in cells transfected with an empty vector. Activation of PKC by application of PMA, a specific PKC activator, increased the ∆F observed in response to application of hypotonic solution (Fig. 1A). TRPV4 has been reported to be directly activated by phorbol esters at high concentrations (56;57), so to eliminate this direct effect as a possible explanation for sensitization we removed PMA before applying the first test pulse of hypotonic solution (see Fig. 1A). We calculated the ratio between the values of ∆F when sensitization had reached a peak to that immediately before exposure to PMA (arrows in Fig. 1A). Without PMA, the distribution of these ratios was well fitted by a Gaussian function (Figure 1B). As an index of the sensitization of TRPV4 following exposure to PMA we calculated the percentage of cells in which the ratio exceeded the 95% confidence limit of the control distribution (see Fig. 1B). Sensitization was markedly inhibited by the broad-spectrum kinase inhibitor staurosporine, by the PKC-specific inhibitor bisindolylmaleimide I (BIM), and by the inhibitor rottlerin (Figure 1C). We note that rottlerin had been proposed to be a specific inhibitor of  PKC but is now thought to be less specific or even to act by other routes (58). In summary, these experiments suggest that phosphorylation by PKC plays an important role in the sensitization of TRPV4.
Bradykinin causes sensitization of TRPV1 by activating PKCε (59), which in turn potentiates activation of TRPV1 by phosphorylating serine residues 502 and 800 (residue numbering for rat TRPV1, see 60). NGF causes sensitization of TRPV1 by activating the tyrosine kinase Src which phosphorylates human TRPV1 at tyrosine 200 (61). We therefore investigated whether bradykinin and NGF can sensitize TRPV4 by co-transfecting the appropriate receptors with TRPV4 (see Methods). There was no significant increase in the percentage of sensitized cell following exposure to NGF. Bradykinin, however, gave a significant enhancement (Figure 1 D) showing that activation of PKC by a physiologically important pro-inflammatory mediator can potentiate gating of TRPV4. No enhancement was observed in the absence of transfected B2 receptors (not shown).
TRPV4 serine and threonine residues involved in sensitization by PKC Using in silico prediction methods we identified 7 serine or threonine residues in the TRPV4 N terminal cytoplasmic domain as candidate substrates for PKC-dependent phosphorylation (Figure 1E). Although these residues could potentially be phosphorylated by PKC not all may in practice be accessible to the kinase, so to identify the functionally important sites these serine or threonine residues were individually replaced with alanine, and the resulting mutant proteins were investigated for enhancement following PKC activation as above. Sensitization of the majority of the single mutants was not significantly different from that observed for wild-type TRPV4, but three of the candidate PKC phosphorylation sites, S162, T175 and S189, showed a significantly lower enhancement when compared to WT TRPV4 (Fig. 1H). The double mutant S189A/T175A (Figure 1F) did not totally abolish PMA-induced sensitization, but mutating all three sites simultaneously completely abolished functional sensitization following PMA application with no significant effect on the activation of TRPV4 by hypotonic solution (Figure 1G, H). 
TRPV4 sensitization by PKC is associated with increased serine phosphorylation. We quantified total serine phosphorylation of TRPV4 with an anti-phosphoserine antibody. TRPV4 was observed to be partially phosphorylated in the basal state, and following exposure to PMA the normalized band density increased by approximately 2 fold (Fig. 2A, B). Mutating the three phosphorylation sites identified above (S162A/T175A/S189A) inhibited the increased level of phosphorylation following exposure to PMA, as did exposure to the inhibitor rottlerin (Fig. 2A, B). 
TRPV4 sensitization by PKA. Application of the adenylate cyclase activator FSK increased ∆F in a subpopulation of TRPV4-transfected cells (Fig. 3A, C). The specific PKA inhibitor H89 (5M) abolished the sensitization of TRPV4 by FSK (Fig. 3B, C). Using in silico methods we identified six S/T residues in the TRPV4 N and C terminal domains as candidate substrates for PKA-dependent phosphorylation (Figure 3D). These residues were individually replaced with alanine, and the resulting mutant proteins were subjected to functional analysis as above. Most mutants were found to exhibit sensitization in response to PKA activation similar to WT TRPV4, but mutation of one C-terminal residue, S824, largely inhibited the sensitization caused by FSK (Fig 3E, F). 
AKAP79 binds to and enhances sensitization of TRPV4 by PKA and PKC. AKAP79 binds to several members of the thermo-TRP family of ion channels, most strongly to TRPV1 and TRPV4 (45). The binding to TRPV4 suggests that AKAP79 may play a role in PKA and PKC-mediated sensitization of TRPV4, as it does in the case of TRPV1 (45). We therefore investigated whether AKAP79 mediates PKA and PKC-dependent sensitization of TRPV4. 
Co-expression of TRPV4 and AKAP79 enhances sensitization by FSK (Figure 4A and E) and by PMA (Figure 4C and F), showing that augmenting the endogenous levels of AKAP79 enhances the sensitization of TRPV4 by both PKA and PKC. We next down-regulated endogenous expression of AKAP79 by the use of siRNA against AKAP79, which was co-expressed with GFP in the same vector to allow identification of transfected cells. In HEK293 cells transfected with siRNA against AKAP79 the expression of AKAP79 is reduced to 10% or less (45). 
In Ca imaging experiments the background fluorescence caused by the transfected GFP can be seen as an enhanced baseline (Fig. 4B, D). Figure 4B shows that downregulation of AKAP79 almost completely inhibits sensitization by FSK (results summarized in Fig. 4 E).  Figure 4D shows that a similar abolition of the sensitization caused by PMA is also observed when AKAP79 is downregulated (results summarized in Fig. 4F). Thus the presence of AKAP79 is essential for the functional sensitization of TRPV4 by both PKA and PKC.
AKAP79 enhances phosphorylation of TRPV4 by PKA and PKC Activation of PKA with FSK caused only a marginal enhancement of TRPV4 serine phosphorylation (Fig 5A), probably because phosphorylation at the single S824 site identified above does not have a powerful effect in raising overall phosphorylation above the baseline level caused by background phosphorylation of other sites. Transfection of AKAP79 or downregulation of AKAP79 using siRNA also had only small effects on TRPV4 phosphorylation levels (Fig. 5A, C). However, the combined effects of transfection of AKAP79 together with activation of PKA with FSK did cause a significantly enhanced level of serine phosphorylation (Fig. 5A, C). 




The TRPV4 ion channel shows substantial homology to TRPV1, the first member of the vanilloid subclass of TRP ion channels to be cloned. Like TRPV1, TRPV4 is activated by a wide range of stimuli, which amongst the possible physiological activators include membrane stretch caused by cell swelling or mechanical stress; warm temperatures above c. 27ºC; low pH; nitric oxide; and a variety of intracellular lipid messengers. The physiological role of TRPV4, and which of these possible activating stimuli is physiologically relevant, remains unknown. TRPV4 is highly expressed in renal nephron and in hypothalamus, and through its osmosensory properties may play a role in regulating body fluids (62;63), but is also expressed in bladder epithelium, where it may play a role in bladder voiding (64;65) and in sensory neurons, where roles both in detection of strong mechanical stimuli (66) and sensation of warm temperatures (67) have been proposed. 
Tissue damage and inflammation cause the release of a range of pro-inflammatory mediators, with bradykinin and prostaglandins prominent among them. These mediators activate of intracellular signaling pathways and downstream kinases, amongst which PKA and PKC are known to be physiologically important (28). Both PKA and PKC enhance activation of TRPV1 (68). In the present paper we examined whether TRPV4 is modulated in a similar way to TRPV1 by phosphorylation by PKA and PKC. We used membrane stretch as a convenient activator of TRPV4, and we monitored activation of TRPV4 from the calcium influx when the channel opens. We carried out our experiments in a HEK293 cell expression system. We note that in the case of the related TRPV1 ion channel, studies in our lab and elsewhere have found that expression systems provide a highly reliable guide to the behaviour of the ion channel in its native environment (45; 69;70).
Activation of PKC by PMA, a potent and specific activator, substantially enhanced both the gating and the phosphorylation of TRPV4. The physiological pro-inflammatory mediator bradykinin, which activates Gq and hence PKC, also potentiated activation of TRPV4. The effect of PMA was inhibited by the broad-spectrum kinase inhibitor staurosporine, by the specific PKC inhibitor BIM I and by the inhibitor rottlerin, which has been proposed to be a specific inhibitor of PKC (but see 58). These results show that PKC sensitizes TRPV4, as it does in the case of TRPV1. We indentified three phosporylation sites close together in the N-terminal domain, S162, T175, and S189, mutation of each of which partially inhibited the enhancement caused by PKC. Mutation of other candidate residues was without effect. Mutation of all three sites together completely abolished the effect of PKC activation without a significant effect on gating of TRPV4. Similar experiments on TRPV1 have also identified candidate PKC phosphorylation sites, but in different parts of the molecule: S502 located in the S2-S3 linker, close to the binding site for capsaicin, and S801 located in the C terminal domain (71;72).
Activation of PKA by application of the adenylate cyclase activator FSK also enhanced gating of TRPV4. The specific PKA inhibitor H89 abolished the effect of FSK, confirming that PKA is involved. A number of candidate phosphorylation sites was investigated, and amongst these a substantial inhibition of the enhancement, though not a complete abolition, was observed following mutation of a single site, S824, in the C-terminal domain. 
Finally, by using a combination of co-expression and knock down approaches, AKAP79 was shown to play a vital role in tethering PKA and PKC to TRPV4 in order to modulate its gating. Functional studies using calcium imaging showed that AKAP79 overexpression enhanced sensitization of TRPV4 by FSK (Figure 4A and E) and PMA (Figure 4B and F), while downregulation of AKAP79 using siRNA inhibited sensitization. These functional studies were supported by studies of the effect of AKAP79 overexpression or downregulation on the phosphorylation of TRPV4, in which it was shown that overexpression of AKAP79 enhanced the phosphorylation induced by PMA (Figure 5C and D), while knockdown with siRNA against AKAP79 decreased the effect of PKC activation on phosphorylation (Figure 5C and D). 









References	1. 	Strotmann, R., Harteneck, C., Nunnenmacher, K., Schultz, G., and Plant, T. D. (2000) Nat.Cell Biol. 2, 695-702	2. 	Liedtke, W., Choe, Y., Marti-Renom, M. A., Bell, A. M., Denis, C. S., Sali, A., Hudspeth, A. J., Friedman, J. M., and Heller, S. (2000) Cell 103, 525-535	3. 	Wissenbach, U., Bodding, M., Freichel, M., and Flockerzi, V. (2000) FEBS Lett. 485, 127-134	4. 	Delany, N. S., Hurle, M., Facer, P., Alnadaf, T., Plumpton, C., Kinghorn, I., See, C. G., Costigan, M., Anand, P., Woolf, C. J., Crowther, D., Sanseau, P., and Tate, S. N. (2001) Physiol Genomics 4, 165-174	5. 	Liedtke, W., Choe, Y., Marti-Renom, M. A., Bell, A. M., Denis, C. S., Sali, A., Hudspeth, A. J., Friedman, J. M., and Heller, S. (2000) Cell 103, 525-535	6. 	Alessandri-Haber, N., Yeh, J. J., Boyd, A. E., Parada, C. A., Chen, X., Reichling, D. B., and Levine, J. D. (2003) Neuron 39, 497-511	7. 	Gao, X., Wu, L., and O'neil, R. G. (2003) J.Biol.Chem. 278, 27129-27137	8. 	Nilius, B., Prenen, J., Wissenbach, U., Bodding, M., and Droogmans, G. (2001) Pflugers Arch. 443, 227-233	9. 	Vriens, J., Watanabe, H., Janssens, A., Droogmans, G., Voets, T., and Nilius, B. (2004) Proc.Natl.Acad.Sci.U.S.A 101, 396-401	10. 	Birder, L., Kullmann, F. A., Lee, H., Barrick, S., de Groat, W., Kanai, A., and Caterina, M. (2007) J Pharmacol.Exp.Ther. 323, 227-235	11. 	Gao, X., Wu, L., and O'neil, R. G. (2003) J.Biol.Chem. 278, 27129-27137	12. 	Guler, A. D., Lee, H., Iida, T., Shimizu, I., Tominaga, M., and Caterina, M. (2002) J.Neurosci. 22, 6408-6414	13. 	Watanabe, H., Vriens, J., Suh, S. H., Benham, C. D., Droogmans, G., and Nilius, B. (2002) J.Biol.Chem. 277, 47044-47051	14. 	Watanabe, H., Davis, J. B., Smart, D., Jerman, J. C., Smith, G. D., Hayes, P., Vriens, J., Cairns, W., Wissenbach, U., Prenen, J., Flockerzi, V., Droogmans, G., Benham, C. D., and Nilius, B. (2002) J.Biol.Chem. 277, 13569-13577	15. 	Xu, F., Satoh, E., and Iijima, T. (2003) Br.J.Pharmacol. 140, 413-421	16. 	Suzuki, M., Mizuno, A., Kodaira, K., and Imai, M. (2003) J.Biol.Chem. 278, 22664-22668	17. 	Vriens, J., Owsianik, G., Fisslthaler, B., Suzuki, M., Janssens, A., Voets, T., Morisseau, C., Hammock, B. D., Fleming, I., Busse, R., and Nilius, B. (2005) Circ.Res. 97, 908-915	18. 	Watanabe, H., Vriens, J., Prenen, J., Droogmans, G., Voets, T., and Nilius, B. (2003) Nature 424, 434-438	19. 	Smith, P. L., Maloney, K. N., Pothen, R. G., Clardy, J., and Clapham, D. E. (2006) J.Biol.Chem. 281, 29897-29904	20. 	Yoshida, T., Inoue, R., Morii, T., Takahashi, N., Yamamoto, S., Hara, Y., Tominaga, M., Shimizu, S., Sato, Y., and Mori, Y. (2006) Nat.Chem.Biol. 2, 596-607	21. 	Liedtke, W., Choe, Y., Marti-Renom, M. A., Bell, A. M., Denis, C. S., Sali, A., Hudspeth, A. J., Friedman, J. M., and Heller, S. (2000) Cell 103, 525-535	22. 	Strotmann, R., Harteneck, C., Nunnenmacher, K., Schultz, G., and Plant, T. D. (2000) Nat.Cell Biol. 2, 695-702	23. 	Wissenbach, U., Bodding, M., Freichel, M., and Flockerzi, V. (2000) FEBS Lett. 485, 127-134	24. 	Liedtke, W., Choe, Y., Marti-Renom, M. A., Bell, A. M., Denis, C. S., Sali, A., Hudspeth, A. J., Friedman, J. M., and Heller, S. (2000) Cell 103, 525-535	25. 	Strotmann, R., Harteneck, C., Nunnenmacher, K., Schultz, G., and Plant, T. D. (2000) Nat.Cell Biol. 2, 695-702	26. 	Wissenbach, U., Bodding, M., Freichel, M., and Flockerzi, V. (2000) FEBS Lett. 485, 127-134	27. 	Alessandri-Haber, N., Dina, O. A., Joseph, E. K., Reichling, D., and Levine, J. D. (2006) J.Neurosci. 26, 3864-3874	28. 	Huang, J., Zhang, X., and McNaughton, P. A. (2006) Semin.Cell Dev.Biol. 17, 638-645	29. 	Cesare, P. and McNaughton, P. (1996) Proc.Natl.Acad.Sci.U.S.A 93, 15435-15439	30. 	Cesare, P., Dekker, L. V., Sardini, A., Parker, P. J., and McNaughton, P. A. (1999) Neuron 23, 617-624	31. 	Bhave, G., Zhu, W., Wang, H., Brasier, D. J., Oxford, G. S., and Gereau, R. W. (2002) Neuron 35, 721-731	32. 	Cesare, P. and McNaughton, P. (1996) Proc.Natl.Acad.Sci.U.S.A 93, 15435-15439	33. 	Cesare, P., Dekker, L. V., Sardini, A., Parker, P. J., and McNaughton, P. A. (1999) Neuron 23, 617-624	34. 	Numazaki, M., Tominaga, T., Toyooka, H., and Tominaga, M. (2002) J Biol Chem	35. 	Bhave, G., Hu, H. J., Glauner, K. S., Zhu, W., Wang, H., Brasier, D. J., Oxford, G. S., and Gereau, R. W. (2003) Proc.Natl.Acad.Sci.U.S.A 100, 12480-12485	36. 	Levine, J. D. and Reichling, D. B. (1999) Peripheral mechanisms of inflammatory pain. In: Wall PD, Melzack R, editors. Textbook of pain. 4th ed. London (U.K.).	37. 	Cunha, F. Q., Teixeira, M. M., and Ferreira, S. H. (1999) Br.J.Pharmacol. 127, 671-678	38. 	Taiwo, Y. O., Bjerknes, L. K., Goetzl, E. J., and Levine, J. D. (1989) Neuroscience 32, 577-580	39. 	Taiwo, Y. O. and Levine, J. D. (1991) Neuroscience 44, 131-135	40. 	Smith, F. D., Langeberg, L. K., and Scott, J. D. (2006) Trends Biochem.Sci. 31, 316-323	41. 	Altier, C., Dubel, S. J., Barrere, C., Jarvis, S. E., Stotz, S. C., Spaetgens, R. L., Scott, J. D., Cornet, V., De, W. M., Zamponi, G. W., Nargeot, J., and Bourinet, E. (2002) J.Biol.Chem. 277, 33598-33603	42. 	Colledge, M., Dean, R. A., Scott, G. K., Langeberg, L. K., Huganir, R. L., and Scott, J. D. (2000) Neuron 27, 107-119	43. 	Hoshi, N., Langeberg, L. K., and Scott, J. D. (2005) Nat.Cell Biol. 7, 1066-1073	44. 	Hoshi, N., Zhang, J. S., Omaki, M., Takeuchi, T., Yokoyama, S., Wanaverbecq, N., Langeberg, L. K., Yoneda, Y., Scott, J. D., Brown, D. A., and Higashida, H. (2003) Nat.Neurosci. 6, 564-571	45. 	Zhang, X., Li, L., and McNaughton, P. A. (2008) Neuron 59, 450-461	46. 	Zhou, F. F., Xue, Y., Chen, G. L., and Yao, X. (2004) Biochem.Biophys.Res.Commun. 325, 1443-1448	47. 	Kim, J. H., Lee, J., Oh, B., Kimm, K., and Koh, I. (2004) Bioinformatics. 20, 3179-3184	48. 	Blom, N., Sicheritz-Ponten, T., Gupta, R., Gammeltoft, S., and Brunak, S. (2004) Proteomics. 4, 1633-1649	49. 	Yaffe, M. B., Leparc, G. G., Lai, J., Obata, T., Volinia, S., and Cantley, L. C. (2001) Nat.Biotechnol. 19, 348-353	50. 	Zhang, X., Huang, J., and McNaughton, P. A. (2005) EMBO J. 24, 4211-4223	51. 	Liedtke, W., Choe, Y., Marti-Renom, M. A., Bell, A. M., Denis, C. S., Sali, A., Hudspeth, A. J., Friedman, J. M., and Heller, S. (2000) Cell 103, 525-535	52. 	Strotmann, R., Harteneck, C., Nunnenmacher, K., Schultz, G., and Plant, T. D. (2000) Nat.Cell Biol. 2, 695-702	53. 	Wissenbach, U., Bodding, M., Freichel, M., and Flockerzi, V. (2000) FEBS Lett. 485, 127-134	54. 	Alessandri-Haber, N., Dina, O. A., Joseph, E. K., Reichling, D., and Levine, J. D. (2006) J.Neurosci. 26, 3864-3874	55. 	Gao, X., Wu, L., and O'neil, R. G. (2003) J.Biol.Chem. 278, 27129-27137	56. 	Watanabe, H., Davis, J. B., Smart, D., Jerman, J. C., Smith, G. D., Hayes, P., Vriens, J., Cairns, W., Wissenbach, U., Prenen, J., Flockerzi, V., Droogmans, G., Benham, C. D., and Nilius, B. (2002) J.Biol.Chem. 277, 13569-13577	57. 	Xu, F., Satoh, E., and Iijima, T. (2003) Br.J.Pharmacol. 140, 413-421	58. 	Soltoff, S. P. (2007) Trends Pharmacol.Sci. 28, 453-458	59. 	Cesare, P., Dekker, L. V., Sardini, A., Parker, P. J., and McNaughton, P. A. (1999) Neuron 23, 617-624	60. 	Numazaki, M., Tominaga, T., Toyooka, H., and Tominaga, M. (2002) J Biol Chem	61. 	Zhang, X., Huang, J., and McNaughton, P. A. (2005) EMBO J. 24, 4211-4223	62. 	Liedtke, W., Choe, Y., Marti-Renom, M. A., Bell, A. M., Denis, C. S., Sali, A., Hudspeth, A. J., Friedman, J. M., and Heller, S. (2000) Cell 103, 525-535	63. 	Liedtke, W. and Friedman, J. M. (2003) Proc.Natl.Acad.Sci.U.S.A 100, 13698-13703	64. 	Gevaert, T., Vriens, J., Segal, A., Everaerts, W., Roskams, T., Talavera, K., Owsianik, G., Liedtke, W., Daelemans, D., Dewachter, I., Van Leuven, F., Voets, T., De Ridder, D., and Nilius, B. (2007) J Clin.Invest 117, 3453-3462	65. 	Birder, L., Kullmann, F. A., Lee, H., Barrick, S., de Groat, W., Kanai, A., and Caterina, M. (2007) J Pharmacol.Exp.Ther. 323, 227-235	66. 	Alessandri-Haber, N., Yeh, J. J., Boyd, A. E., Parada, C. A., Chen, X., Reichling, D. B., and Levine, J. D. (2003) Neuron 39, 497-511	67. 	Guler, A. D., Lee, H., Iida, T., Shimizu, I., Tominaga, M., and Caterina, M. (2002) J.Neurosci. 22, 6408-6414	68. 	Huang, J., Zhang, X., and McNaughton, P. A. (2006) Current Neuropharmacology 4, 197-206	69. 	Vellani, V., Mapplebeck, S., Moriondo, A., Davis, J. B., and McNaughton, P. A. (2001) J.Physiol 534, 813-825	70. 	Zhang, X., Huang, J., and McNaughton, P. A. (2005) EMBO J 24, 4211-4223	71. 	Bhave, G., Hu, H. J., Glauner, K. S., Zhu, W., Wang, H., Brasier, D. J., Oxford, G. S., and Gereau, R. W. (2003) Proc.Natl.Acad.Sci.U.S.A 100, 12480-12485	72. 	Numazaki, M., Tominaga, T., Toyooka, H., and Tominaga, M. (2002) J Biol Chem	73. 	Martiny-Baron, G., KAZANIETZ, M. G., Mischak, H., Blumberg, P. M., Kochs, G., Hug, H., Marme, D., and Schachtele, C. (1993) J Biol.Chem. 268, 9194-9197

	1. 	Strotmann, R., Harteneck, C., Nunnenmacher, K., Schultz, G., and Plant, T. D. (2000) Nat.Cell Biol. 2, 695-702
	2. 	Liedtke, W., Choe, Y., Marti-Renom, M. A., Bell, A. M., Denis, C. S., Sali, A., Hudspeth, A. J., Friedman, J. M., and Heller, S. (2000) Cell 103, 525-535
	3. 	Wissenbach, U., Bodding, M., Freichel, M., and Flockerzi, V. (2000) FEBS Lett. 485, 127-134
	4. 	Delany, N. S., Hurle, M., Facer, P., Alnadaf, T., Plumpton, C., Kinghorn, I., See, C. G., Costigan, M., Anand, P., Woolf, C. J., Crowther, D., Sanseau, P., and Tate, S. N. (2001) Physiol Genomics 4, 165-174
	5. 	Liedtke, W., Choe, Y., Marti-Renom, M. A., Bell, A. M., Denis, C. S., Sali, A., Hudspeth, A. J., Friedman, J. M., and Heller, S. (2000) Cell 103, 525-535
	6. 	Alessandri-Haber, N., Yeh, J. J., Boyd, A. E., Parada, C. A., Chen, X., Reichling, D. B., and Levine, J. D. (2003) Neuron 39, 497-511
	7. 	Gao, X., Wu, L., and O'neil, R. G. (2003) J.Biol.Chem. 278, 27129-27137
	8. 	Nilius, B., Prenen, J., Wissenbach, U., Bodding, M., and Droogmans, G. (2001) Pflugers Arch. 443, 227-233
	9. 	Vriens, J., Watanabe, H., Janssens, A., Droogmans, G., Voets, T., and Nilius, B. (2004) Proc.Natl.Acad.Sci.U.S.A 101, 396-401
	10. 	Birder, L., Kullmann, F. A., Lee, H., Barrick, S., de Groat, W., Kanai, A., and Caterina, M. (2007) J Pharmacol.Exp.Ther. 323, 227-235
	11. 	Gao, X., Wu, L., and O'neil, R. G. (2003) J.Biol.Chem. 278, 27129-27137
	12. 	Guler, A. D., Lee, H., Iida, T., Shimizu, I., Tominaga, M., and Caterina, M. (2002) J.Neurosci. 22, 6408-6414
	13. 	Watanabe, H., Vriens, J., Suh, S. H., Benham, C. D., Droogmans, G., and Nilius, B. (2002) J.Biol.Chem. 277, 47044-47051
	14. 	Watanabe, H., Davis, J. B., Smart, D., Jerman, J. C., Smith, G. D., Hayes, P., Vriens, J., Cairns, W., Wissenbach, U., Prenen, J., Flockerzi, V., Droogmans, G., Benham, C. D., and Nilius, B. (2002) J.Biol.Chem. 277, 13569-13577
	15. 	Xu, F., Satoh, E., and Iijima, T. (2003) Br.J.Pharmacol. 140, 413-421
	16. 	Suzuki, M., Mizuno, A., Kodaira, K., and Imai, M. (2003) J.Biol.Chem. 278, 22664-22668
	17. 	Vriens, J., Owsianik, G., Fisslthaler, B., Suzuki, M., Janssens, A., Voets, T., Morisseau, C., Hammock, B. D., Fleming, I., Busse, R., and Nilius, B. (2005) Circ.Res. 97, 908-915
	18. 	Watanabe, H., Vriens, J., Prenen, J., Droogmans, G., Voets, T., and Nilius, B. (2003) Nature 424, 434-438
	19. 	Smith, P. L., Maloney, K. N., Pothen, R. G., Clardy, J., and Clapham, D. E. (2006) J.Biol.Chem. 281, 29897-29904
	20. 	Yoshida, T., Inoue, R., Morii, T., Takahashi, N., Yamamoto, S., Hara, Y., Tominaga, M., Shimizu, S., Sato, Y., and Mori, Y. (2006) Nat.Chem.Biol. 2, 596-607
	21. 	Liedtke, W., Choe, Y., Marti-Renom, M. A., Bell, A. M., Denis, C. S., Sali, A., Hudspeth, A. J., Friedman, J. M., and Heller, S. (2000) Cell 103, 525-535
	22. 	Strotmann, R., Harteneck, C., Nunnenmacher, K., Schultz, G., and Plant, T. D. (2000) Nat.Cell Biol. 2, 695-702
	23. 	Wissenbach, U., Bodding, M., Freichel, M., and Flockerzi, V. (2000) FEBS Lett. 485, 127-134
	24. 	Liedtke, W., Choe, Y., Marti-Renom, M. A., Bell, A. M., Denis, C. S., Sali, A., Hudspeth, A. J., Friedman, J. M., and Heller, S. (2000) Cell 103, 525-535
	25. 	Strotmann, R., Harteneck, C., Nunnenmacher, K., Schultz, G., and Plant, T. D. (2000) Nat.Cell Biol. 2, 695-702
	26. 	Wissenbach, U., Bodding, M., Freichel, M., and Flockerzi, V. (2000) FEBS Lett. 485, 127-134
	27. 	Alessandri-Haber, N., Dina, O. A., Joseph, E. K., Reichling, D., and Levine, J. D. (2006) J.Neurosci. 26, 3864-3874
	28. 	Huang, J., Zhang, X., and McNaughton, P. A. (2006) Semin.Cell Dev.Biol. 17, 638-645
	29. 	Cesare, P. and McNaughton, P. (1996) Proc.Natl.Acad.Sci.U.S.A 93, 15435-15439
	30. 	Cesare, P., Dekker, L. V., Sardini, A., Parker, P. J., and McNaughton, P. A. (1999) Neuron 23, 617-624
	31. 	Bhave, G., Zhu, W., Wang, H., Brasier, D. J., Oxford, G. S., and Gereau, R. W. (2002) Neuron 35, 721-731
	32. 	Cesare, P. and McNaughton, P. (1996) Proc.Natl.Acad.Sci.U.S.A 93, 15435-15439
	33. 	Cesare, P., Dekker, L. V., Sardini, A., Parker, P. J., and McNaughton, P. A. (1999) Neuron 23, 617-624
	34. 	Numazaki, M., Tominaga, T., Toyooka, H., and Tominaga, M. (2002) J Biol Chem
	35. 	Bhave, G., Hu, H. J., Glauner, K. S., Zhu, W., Wang, H., Brasier, D. J., Oxford, G. S., and Gereau, R. W. (2003) Proc.Natl.Acad.Sci.U.S.A 100, 12480-12485
	36. 	Levine, J. D. and Reichling, D. B. (1999) Peripheral mechanisms of inflammatory pain. In: Wall PD, Melzack R, editors. Textbook of pain. 4th ed. London (U.K.).
	37. 	Cunha, F. Q., Teixeira, M. M., and Ferreira, S. H. (1999) Br.J.Pharmacol. 127, 671-678
	38. 	Taiwo, Y. O., Bjerknes, L. K., Goetzl, E. J., and Levine, J. D. (1989) Neuroscience 32, 577-580
	39. 	Taiwo, Y. O. and Levine, J. D. (1991) Neuroscience 44, 131-135
	40. 	Smith, F. D., Langeberg, L. K., and Scott, J. D. (2006) Trends Biochem.Sci. 31, 316-323
	41. 	Altier, C., Dubel, S. J., Barrere, C., Jarvis, S. E., Stotz, S. C., Spaetgens, R. L., Scott, J. D., Cornet, V., De, W. M., Zamponi, G. W., Nargeot, J., and Bourinet, E. (2002) J.Biol.Chem. 277, 33598-33603
	42. 	Colledge, M., Dean, R. A., Scott, G. K., Langeberg, L. K., Huganir, R. L., and Scott, J. D. (2000) Neuron 27, 107-119
	43. 	Hoshi, N., Langeberg, L. K., and Scott, J. D. (2005) Nat.Cell Biol. 7, 1066-1073
	44. 	Hoshi, N., Zhang, J. S., Omaki, M., Takeuchi, T., Yokoyama, S., Wanaverbecq, N., Langeberg, L. K., Yoneda, Y., Scott, J. D., Brown, D. A., and Higashida, H. (2003) Nat.Neurosci. 6, 564-571
	45. 	Zhang, X., Li, L., and McNaughton, P. A. (2008) Neuron 59, 450-461
	46. 	Zhou, F. F., Xue, Y., Chen, G. L., and Yao, X. (2004) Biochem.Biophys.Res.Commun. 325, 1443-1448
	47. 	Kim, J. H., Lee, J., Oh, B., Kimm, K., and Koh, I. (2004) Bioinformatics. 20, 3179-3184
	48. 	Blom, N., Sicheritz-Ponten, T., Gupta, R., Gammeltoft, S., and Brunak, S. (2004) Proteomics. 4, 1633-1649
	49. 	Yaffe, M. B., Leparc, G. G., Lai, J., Obata, T., Volinia, S., and Cantley, L. C. (2001) Nat.Biotechnol. 19, 348-353
	50. 	Zhang, X., Huang, J., and McNaughton, P. A. (2005) EMBO J. 24, 4211-4223
	51. 	Liedtke, W., Choe, Y., Marti-Renom, M. A., Bell, A. M., Denis, C. S., Sali, A., Hudspeth, A. J., Friedman, J. M., and Heller, S. (2000) Cell 103, 525-535
	52. 	Strotmann, R., Harteneck, C., Nunnenmacher, K., Schultz, G., and Plant, T. D. (2000) Nat.Cell Biol. 2, 695-702
	53. 	Wissenbach, U., Bodding, M., Freichel, M., and Flockerzi, V. (2000) FEBS Lett. 485, 127-134
	54. 	Alessandri-Haber, N., Dina, O. A., Joseph, E. K., Reichling, D., and Levine, J. D. (2006) J.Neurosci. 26, 3864-3874
	55. 	Gao, X., Wu, L., and O'neil, R. G. (2003) J.Biol.Chem. 278, 27129-27137
	56. 	Watanabe, H., Davis, J. B., Smart, D., Jerman, J. C., Smith, G. D., Hayes, P., Vriens, J., Cairns, W., Wissenbach, U., Prenen, J., Flockerzi, V., Droogmans, G., Benham, C. D., and Nilius, B. (2002) J.Biol.Chem. 277, 13569-13577
	57. 	Xu, F., Satoh, E., and Iijima, T. (2003) Br.J.Pharmacol. 140, 413-421
	58. 	Soltoff, S. P. (2007) Trends Pharmacol.Sci. 28, 453-458
	59. 	Cesare, P., Dekker, L. V., Sardini, A., Parker, P. J., and McNaughton, P. A. (1999) Neuron 23, 617-624
	60. 	Numazaki, M., Tominaga, T., Toyooka, H., and Tominaga, M. (2002) J Biol Chem
	61. 	Zhang, X., Huang, J., and McNaughton, P. A. (2005) EMBO J. 24, 4211-4223
	62. 	Liedtke, W., Choe, Y., Marti-Renom, M. A., Bell, A. M., Denis, C. S., Sali, A., Hudspeth, A. J., Friedman, J. M., and Heller, S. (2000) Cell 103, 525-535
	63. 	Liedtke, W. and Friedman, J. M. (2003) Proc.Natl.Acad.Sci.U.S.A 100, 13698-13703
	64. 	Gevaert, T., Vriens, J., Segal, A., Everaerts, W., Roskams, T., Talavera, K., Owsianik, G., Liedtke, W., Daelemans, D., Dewachter, I., Van Leuven, F., Voets, T., De Ridder, D., and Nilius, B. (2007) J Clin.Invest 117, 3453-3462
	65. 	Birder, L., Kullmann, F. A., Lee, H., Barrick, S., de Groat, W., Kanai, A., and Caterina, M. (2007) J Pharmacol.Exp.Ther. 323, 227-235
	66. 	Alessandri-Haber, N., Yeh, J. J., Boyd, A. E., Parada, C. A., Chen, X., Reichling, D. B., and Levine, J. D. (2003) Neuron 39, 497-511
	67. 	Guler, A. D., Lee, H., Iida, T., Shimizu, I., Tominaga, M., and Caterina, M. (2002) J.Neurosci. 22, 6408-6414
	68. 	Huang, J., Zhang, X., and McNaughton, P. A. (2006) Current Neuropharmacology 4, 197-206
	69. 	Vellani, V., Mapplebeck, S., Moriondo, A., Davis, J. B., and McNaughton, P. A. (2001) J.Physiol 534, 813-825
	70. 	Zhang, X., Huang, J., and McNaughton, P. A. (2005) EMBO J 24, 4211-4223
	71. 	Bhave, G., Hu, H. J., Glauner, K. S., Zhu, W., Wang, H., Brasier, D. J., Oxford, G. S., and Gereau, R. W. (2003) Proc.Natl.Acad.Sci.U.S.A 100, 12480-12485
	72. 	Numazaki, M., Tominaga, T., Toyooka, H., and Tominaga, M. (2002) J Biol Chem





Figure 1 TRPV4 is sensitised by activation of PKC. 





Figure 2 TRPV4 is phosphorylated in response to activation of PKC. 





Figure 3. TRPV4 is sensitised by activation of PKA.





















Figure 4 Effects of AKAP79 on sensitization of TRPV4 by PKA and PKC activation










Figure 5 AKAP79 enhances TRPV4 phosphorylation levels following activation of PKA and PKC.
(A) Upper panel shows serine phosphorylation level of TRPV4 following activation of PKA (treatment with 100μM FSK for 40 minutes, 1st, 4th and 5th lanes). Lower panel shows same membrane reprobed with anti-V5 antibody to control for variations in TRPV1 expression. Phosphoserine (PS) level was strongly enhanced following exposure to FSK in cells coexpressing TRPV4 and AKAP79 (5th lane). (B) Similar experiment in which PKC was activated with PMA (1μM, 20 minutes, 2nd, 3rd and 5th lanes). (C) Summary of experiments with PKA activation, similar to that shown in A. PS band density normalized to TRPV1 band density (lower panel in A) and expressed relative to level in absence of FSK and AKAP (col, 1). Bars show mean ± S.E.M (n=3). Significance level *, p < 0.05 compared to bar 1. (D) Summary of experiments with PKC activation, similar to that shown in B. Significance levels *, p < 0.05; **, p < 0.01 (n=3) compared to bar 1(comparisons shown above bars), and compared to bar 3 (comparisons shown below bars).
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